Retreatment with monoclonal antibodies targeting the anti-epidermal growth factor receptors (anti-EGFRs) is a promising approach for RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients who developed acquired resistance to previous anti-EGFR exposure (1–6). The gene discussed is EGFR; the disease is metastatic colorectal cancer.